Introduction {#sec1}
============

Amyloidosis is a disorder of protein metabolism characterised by the deposition of amyloid protein fibrils in the extracellular spaces of different body tissues. It may remain localised to a single organ or present as a systemic disorder involving multiple organs.[@bib1], [@bib5] Primary localised amyloidosis of the urinary bladder is a rare condition, first described by Solomin in 1897,[@bib1] with less than 200 cases reported worldwide.[@bib2] The main presentations of primary amyloidosis of the urinary bladder are intermittent, painless frank haematuria with irritative voiding symptoms.[@bib1], [@bib2], [@bib3] The condition can be easily mistaken for a malignancy on the basis of imaging and cystoscopy findings.[@bib6], [@bib7] Therefore, transurethral resection of the lesion and histopathological examination are considered the standard strategy for diagnosis and treatment and to exclude malignancy.[@bib6], [@bib7]

Case report {#sec1.1}
-----------

A 41-year-old man presented for the first time to the Accident and Emergency department in 2012 complaining of haematuria that lasted for 10 days duration that was intermittent, painless, terminal and frank, with passage of clots associated with mild dysuria. The patient was a non-smoker with no comorbidities.

The results of a urinalysis and a urine culture were negative. His urine cytology showed atypical urothelial cells and was negative for malignancy. Ultrasound of the kidney, ureters and bladder revealed a normal upper urinary tract and two echogenic lesions measuring 0.87 × 0.65 cm and 1.7 × 1.4 cm, respectively, in the posterior wall of the urinary bladder ([Figure 1](#fig1){ref-type="fig"}).Figure 1Ultrasonographic image showing a bladder mass.

He underwent a cystoscopy that revealed a polypoid nodular lesion measuring approximately 2 cm in size, with hyperaemia and ulceration involving the posterior bladder wall; this was highly suggestive of malignancy. Both ureteric orifices were not affected by the lesion. Transurethral resection of the lesion was performed. His histopathological findings were consistent with amyloidosis and were confirmed using special stains such as CD 138, Congo red, and haematoxylin & eosin (H&E) ([Figure 2](#fig2){ref-type="fig"}a,b,c).Figure 2a: Histopathological examination of a specimen using CD138 stain. b: Histopathological examination of a specimen using Congo red stain. c: Histopathological examination of a specimen using haematoxylin & eosin (H&E) stain.

The patient was fine and appeared healthy at follow-up. Systemic investigations were performed to exclude systemic amyloidosis. His 24-h urine protein electrophoresis and urinary Bence Jones protein test results were negative. Additionally, the sigmoid colon biopsy result was also negative. His electrocardiogram was normal.

One year later he developed similar symptoms and underwent computed tomography (CT) which revealed a plaque-like, focal mural thickening along the left posterolateral aspect of his urinary bladder with a maximal thickness of 4--5 mm ([Figure 3](#fig3){ref-type="fig"}).Figure 3CT scan of the urinary bladder showing bladder wall thickening of 4--5 mm.

Urine cytology was negative for malignancy. He was treated conservatively.

One year later, intermittent, gross painless haematuria with passage of clots recurred. CT was repeated and revealed that the urinary bladder was moderately distended, with focal wall thickening along the left posterolateral aspect with maximum thickness of 9 mm. The vesicoureteral junction was also affected and showed wall thickening ([Figure 4](#fig4){ref-type="fig"}).Figure 4CT scan of the urinary bladder showing bladder wall thickening measuring 9 mm.

The patient was offered a check cystoscopy and transurethral resection of bladder tumour; but he refused and was lost to follow-up for approximately a year. He visited the Accident and Emergency again in November 2016 with painless, intermittent frank haematuria associated with the passage of clots and mild dysuria. All his blood test results were normal, and urine cytology was negative.

CT revealed that the urinary bladder was well distended with an enhancing, plaque-like, focal, nodular, polypoidal mural lesion along its left posterolateral aspect measuring approximately 4.3 × 1.5 cm in size. The adjoining vesicoureteral junction was also affected and showed wall thickening ([Figure 5](#fig5){ref-type="fig"}).Figure 5CT scan of the urinary bladder showing a nodular bladder mass.

He underwent cystoscopy, which showed a nodular lesion with ulceration, hyperaemia and a whitish layer involving almost the entire bladder wall ([Figure 6](#fig6){ref-type="fig"}a and 6b).Figure 6a: Cystoscopic image showing a bladder mass. b: Cystoscopic image showing a bladder mass.

Near-complete transurethral resection of the lesion was performed.

Histopathological findings were consistent with amyloidosis of the urinary bladder.

Presently, the patient has been followed-up postoperatively over 6 months and has been asymptomatic. Should he develop recurrent tumour, re-TURBT has been planned. He has also been re-evaluated to exclude any systemic involvement, which was unproven in the findings.

Discussion {#sec2}
==========

Primary isolated amyloidosis of the urinary bladder is a rare disease with 200 cases reported by Michael et al.[@bib1] The amyloid was first described by Virchow in 1854. The first case of isolated urinary bladder amyloidosis was described by Solomin in 1897.[@bib1] This condition is a disease of protein metabolism characterised by amyloid protein fibril deposition in the extracellular spaces of body tissues. Most patients with primary urinary bladder amyloidosis commonly present with intermittent, painless gross haematuria and some of them presented with irritative urinary symptoms that mimic transitional cell carcinoma.[@bib4], [@bib9], [@bib10] The disease is commonly seen in patients aged 50--70 years and the amyloid deposition is found predominantly in the posterior bladder wall (68%), followed by in the trigone (26%).[@bib15] The aetiology of localised primary amyloidosis is unknown. According to the proposed mechanism, chronic inflammation of the bladder causes an influx of lymphoplasmacytic cells into the submucosa of the bladder; these cells become monoclonal cells that secrete an abnormal light chain type immunoglobulin. Transurethral resection of the lesion and histopathological examination are important to establish a diagnosis and to exclude malignancy. Primary urinary bladder amyloidosis shows a high rate of recurrence. Tirzaman et al. followed 31 patients with localised bladder amyloidosis and observed that in 25% of patients the condition resolved and the patients became disease-free, 21% had persistent disease and 54% showed recurrence.[@bib11] Localised amyloidosis of the urinary bladder may not require systemic treatment,[@bib12] and surgical resection and fulguration may be the standard treatment even though other treatment modalities, such as the intravesical administration of dimethyl sulphoxide[@bib13] or the use of oral colchicine,[@bib14] have been reported in literature; however, their clinical utility remains limited. A cystectomy may be indicated in those with severe and uncontrolled haemorrhage. According to literature, this disease requires close long-term follow-up with annual check cystoscopy, as the rate of recurrence is high.

Conclusion {#sec3}
==========

Primary amyloidosis of the urinary bladder is a rare disorder. The aetiology remains unknown and most patients present with intermittent, painless gross haematuria. Cystoscopic and histopathological examination are important to diagnose this condition as it resembles bladder malignancy. This case demonstrates that primary amyloidosis of the urinary bladder is a recurrent and progressive non-malignant disease. Transurethral resection and fulguration of the lesion remain the standard treatment. Long-term follow-up with annual check cystoscopy is recommended, as the rate of recurrence is high.
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